Open AccessInfluence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients
Author(s) -
Norihiko Tsuchiya,
Shigeru Satoh,
Hitoshi Tada,
Zhenhua Li,
Chikara Οhyama,
Kazunari Sato,
Toshio Suzuki,
Tomonori Habuchi,
Takumi Kato
Publication year - 2004
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000137789.58694.b4
Subject(s) - tacrolimus , pharmacokinetics , cyp3a5 , medicine , pharmacology , therapeutic drug monitoring , trough level , gastroenterology , single nucleotide polymorphism , genotype , transplantation , urology , biology , genetics , gene
A body-weight-based dose of tacrolimus often results in marked individual diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450 (CYP) 3A5 and p-glycoprotein encoded by CYP3A5 and MDR1 (ABCB1), respectively, having multiple single nucleotide polymorphisms. In this study, we genotyped CYP3A5 A6986G, MDR1 G2677(A/T), and C3435T polymorphisms and investigated the association between these polymorphisms and the pharmacokinetics of tacrolimus in renal transplant recipients.